Protara Therapeutics (TARA) Change in Accured Expenses (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Change in Accured Expenses data on file, last reported at -$2.6 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 39.14% year-over-year to -$2.6 million in Q1 2026; TTM through Mar 2026 was $89000.0, a 888.89% increase from a year earlier, with the FY2025 full-year figure at $821000.0, down 69.32% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.6 million, down from $2.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for TARA reached as high as $2.0 million in Q4 2025 and fell as low as -$2.6 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$55117.6 across 5 years, with a median of $140000.0 in 2024.
• Across the five-year window, Change in Accured Expenses sank 1898.08% in 2022 and soared 1360.0% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$1.2 million in 2022, then jumped by 114.85% to $177000.0 in 2023, then dropped by 20.9% to $140000.0 in 2024, then surged by 1360.0% to $2.0 million in 2025, then sank by 227.3% to -$2.6 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$2.6 million in Q1 2026, $2.0 million in Q4 2025, and $922000.0 in Q3 2025.